ArticleHaematologica2013
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.
Article in Haematologica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Potential Antiviral Action of Alkaloids.Molecules (Basel, Switzerland) · 2022Review
- Synergistic Lethality Effects of Apatinib and Homoharringtonine in Acute Myeloid Leukemia.Journal of oncology · 2022Article
- How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice.Blood and lymphatic cancer : targets and therapy · 2022Article
- Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma.JCI insight · 2021Article
- Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in theFrontiers in oncology · 2019Article
- A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected.Oncology and therapy · 2018Review
- Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.Molecular cancer · 2018Review
- Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.Drugs & aging · 2016Review
- Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.Leukemia & lymphoma · 2016Article
- Article
- Novel drugs for older patients with acute myeloid leukemia.Leukemia · 2015Review
- Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.OncoTargets and therapy · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.